Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Иммунонутриентные свойства лактоферрина и его защитная роль при новой коронавирусной инфекции COVID-19

https://doi.org/10.33667/2078-5631-2021-21-22-26

Полный текст:

Аннотация

Тысячи исследований были проведены для изучения нового коронавируса SARS-CoV-2, его инфекционных свойств, путей передачи и всего, что связано с клиническими проявлениями и тяжестью COVID-19, особенно потенциальными методами лечения. Лактоферрин -представитель семейства трансферринов, который синтезируется эпителиальными клетками внутренних желез млекопитающих и широко представлен в различных секреторных жидкостях, таких как молоко, слюна, слезы, секрет носовых желез. Лактоферрин является одним из компонентов врожденного гуморального иммунитета, регулирует функции иммунокомпетентных клеток и является белком острой фазы воспаления. Лактоферрин обладает выраженными антиоксидантным и противовоспалительным свойствами. В данном обзоре оценивается возможность использования лактоферрина в программах иммунокорригирующей диетотерапии при вирусных заболеваниях в том числе новой коронавирусной инфекции COVID-19.

Об авторах

С. В. Орлова
Российский университет дружбы народов
Россия

Орлова Светлана Владимировна – доктор медицинских наук, профессор, заведующая кафедрой диетологии и клинической нутрициологии.

Москва.



Е. А. Никитина
Российский университет дружбы народов
Россия

Никитина Елена Александровна - кандидат медицинских наук, доцент кафедры диетологии и клинической нутрициологии.

Москва.



Е. В. Прокопенко
ООО «МС Груп»
Россия

Прокопенко Елена Валерьевна - врач-эндокринолог, диетолог, врач-методолог медицинского департамента.

Москва.



Л. Ю. Волкова
Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России
Россия

Волкова Людмила Юрьевна – кандидат медицинских наук, старший преподаватель отдела организационно-методического управления и анализа качества медицинской помощи.

Москва.



А. Н. Водолазкая
ООО «Эль-Клиник»
Россия

Водолазкая Ангелина Николаевна - врач диетолог-эндокринолог медицинского центра.

Москва.



Список литературы

1. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995 May-Jun; 80 (3): 252 67. PMID: 7672721.

2. Sorensen M, Sorensen SPL. The proteins in whey. C R Trav Lab Carlsb Ser Chim 1940; 23: 55-99.

3. Johanson B, Virtanen AI, Tweit RC, Dodson RM. Isolation of an iron-containing red protein from human milk. Acta Chem Scand 1960; 14: 510-12.

4. Steijns JM, van Hooijdonk AC. Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br J Nutr. 2000 Nov; 84 Suppl 1: S 11-7. DOI: 10.1017/s0007114500002191. PMID: 11242441.

5. Zimecki M, Actor JK, Kruzel ML. The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm. Int Immunopharmacol. 2021 Jun;95:107571. DOI: 10.1016/j.intimp.2021.107571. Epub 2021 Mar 12. PMID: 33765614; PMCID: PMC 7953442.

6. Sinopoli A, Isonne C, Santoro MM, Baccolini V. The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. Rev Med Virol. 2021 May 28: e2261. DOI: 10.1002/rmv.2261. Epub ahead of print. PMID: 34133812.

7. Almeida CC, Mendonca Pereira BF, Leandro KC, Costa MP, Spisso BF, Conte-Junior CA. Bioactive Compounds in Infant Formula and Their Effects on Infant Nutrition and Health: A Systematic Literature Review. Int J Food Sci. 2021 May 14; 2021: 8850080. DOI: 10.1155/2021/8850080. PMID: 34095293; PMCID: PMC 8140835.

8. Lonnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr. 1995; 15: 93-110. DOI: 10.1146/annurev.nu.15.070195.000521. PMID: 8527233.

9. Nairz M, Weiss G. Iron in infection and immunity. Mol Aspects Med. 2020 Oct; 75: 100864. DOI: 10.1016/j.mam.2020.100864. Epub 2020 May 24. PMID: 32461004.

10. Kabyemela ER, Fried M, Kurtis JD, Mutabingwa TK, Duffy PE. Decreased susceptibility to Plasmodium falciparum infection in pregnant women with iron deficiency. J Infect Dis. 2008 Jul 15; 198 (2): 163-6. DOI: 10.1086/589512. PMID: 18500927.

11. Oppenheimer SJ, Gibson FD, Macfarlane SB, Moody JB, Harrison C, Spencer A, Bunari O. Iron supplementation increases prevalence and effects of malaria: report on clinical studies in Papua New Guinea. Trans R Soc Trop Med Hyg. 1986;80(4): 603-12. DOI: 10.1016/0035-9203(86)90154-9. PMID: 3101243.

12. Smith AW, Hendrickse RG, Harrison C, Hayes RJ, Greenwood BM. The effects on malaria of treatment of iron-deficiency anaemia with oral iron in Gambian children. Ann Trop Paediatr. 1989 Mar; 9 (1): 17-23. DOI: 10.1080/02724936.1989.11748589. PMID: 2471438.

13. Gwamaka M, Kurtis JD, Sorensen BE, Holte S, Morrison R, Mutabingwa TK, Fried M, Duffy PE. Iron deficiency protects against severe Plasmodium falciparum malaria and death in young children. Clin Infect Dis. 2012 Apr; 54 (8): 1137-44. DOI: 10.1093/cid/cis010. Epub 2012 Feb 21. PMID: 22354919; PMCID: PMC 3309886.

14. Atkinson SH, Armitage AE, Khandwala S, Mwangi TW, Uyoga S, Bejon PA, Williams TN, Prentice AM, Drakesmith H. Combinatorial effects of malaria season, iron deficiency, and inflammation determine plasma hepcidin concentration in African children. Blood. 2014 May 22; 123 (21): 3221-9. DOI: 10.1182/blood-2013-10-533000. Epub 2014 Mar 4. PMID: 24596418; PMCID: PMC 4046425.

15. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019 Jan 3;133(1): 40-50. DOI: 10.1182/blood-2018-06-856500. Epub 2018 Nov 6. PMID: 30401705; PMCID: PMC 6536698.

16. Melo AKG, Milby KM, Caparroz ALMA, Pinto ACPN, Santos RRP, Rocha AP, Ferreira GA, Souza VA, Valadares LDA, Vieira RMRA, Pileggi GS, Trevisani VFM. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. PLoS One. 2021 Jun 29; 16 (6): e0253894. DOI: 10.1371/journal.pone.0253894. PMID: 34185801; PMCID: PMC 8241122.

17. Bellmann-Weiler R, Lanser L, Barket R, Rangger L, Schapfl A, Schaber M, Fritsche G, Woll E, Weiss G. Prevalence and Predictive Value of Anemia and Dysregulated Iron Homeostasis in Patients with COVID-19 Infection. J Clin Med. 2020 Jul 29; 9 (8): 2429. DOI: 10.3390/jcm9082429. PMID: 32751400; PMCID: PMC 7464087.

18. Sonnweber T, Boehm A, Sahanic S, Pizzini A, Aichner M, Sonnweber B, Kurz K, Koppel-statter S, Haschka D, Petzer V, Hilbe R, TheurlM, Lehner D, Nalrz M, Puchner B, Luger A, Schwabl C, Bellmann-Weiler R, Woll E, Widmann G, Tancevski I, Judith-Loffler-Ragg, Weiss G. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study. Respir Res. 2020 Oct 21; 21 (1): 276. DOI: 10.1186/s12931-020-01546-2. PMID: 33087116; PMCID: PMC 7575703.

19. Habib HM, Ibrahim S, Zaim A, Ibrahim WH. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed Pharmacother. 2021 Apr; 136: 111228. DOI: 10.1016/j.biopha.2021.111228. Epub 2021 Jan 13. PMID: 33454595; PMCID: PMC 7836924.

20. Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH, Meijer DK. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis. 1995 Aug; 172 (2): 380-8. DOI: 10.1093/infdis/172.2.380. PMID: 7622881.

21. Haschka D, Hoffmann A, Weiss G. Iron in immune cell function and host defense. Semin Cell Dev Biol. 2021 Jul; 115: 27-36. DOI: 10.1016/j.semcdb.2020.12.005. Epub 2020 Dec 30. PMID: 33386235.

22. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol. 2008; 606: 163-94. DOI: 10.1007/978-0-387-74087-4_6. PMID: 18183929.

23. Ling JM, Schryvers AB. Perspectives on interactions between lactoferrin and bacteria. Biochem Cell Biol. 2006 Jun; 84 (3): 275-81. DOI: 10.1139/o06-044. PMID: 16936797.

24. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG. Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis. 2003 Jan 1; 187 (1): 87-95. DOI: 10.1086/345875. Epub 2002 Dec 13. PMID: 12508150.

25. Dial EJ, Lichtenberger LM. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol. 2002; 80 (1): 113-7. DOI: 10.1139/o01-205. PMID: 11908634.

26. Lonnerdal B, Erdmann P, Thakkar SK, Sauser J, Destaillats F. Longitudinal evolution of true protein, amino acids and bioactive proteins in breast milk: a developmental perspective. J Nutr Biochem. 2017 Mar; 41: 1-11. DOI: 10.1016/j.jnutbio.2016.06.001. Epub 2016 Jun 21. PMID: 27771491.

27. Ng TB, Cheung RC, Wong JH, Wang Y, Ip DT, Wan DC, Xia J. Antiviral activities of whey proteins. Appl Microbiol Biotechnol. 2015 Sep; 99 (17): 6997-7008. DOI: 10.1007/s00253-015-6818-4. Epub 2015 Jul 22. PMID: 26198883; PMCID: PMC 7080083.

28. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия-11 (07.05.2021).

29. Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G, Jiang C. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011; 6 (8): e23710. DOI: 10.1371/journal.pone.0023710. Epub 2011 Aug 22. PMID: 21887302; PMCID: PMC 3161750.

30. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol. 2004 Oct; 74 (2): 262-71. DOI: 10.1002/jmv.20171. PMID: 15332275.

31. Nozaki A, Ikeda M, Naganuma A, Nakamura T, Inudoh M, Tanaka K, Kato N. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E 2 envelope protein. J Biol Chem. 2003 Mar 21; 278 (12): 10162-73. DOI: 10.1074/jbc.M207879200. Epub 2003 Jan 9. PMID: 12522210.

32. Puddu P, Borghi P, Gessani S, Valenti P, Belardelli F, Seganti L. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int J Biochem Cell Biol. 1998 Sep; 30 (9): 1055-62. DOI: 10.1016/s1357-2725(98)00066-1. PMID: 9785469.

33. Vitetta L, Coulson S, Beck SL, Gramotnev H, Du S, Lewis S. The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study. Complement Ther Med. 2013 Jun; 21 (3): 164-71. DOI: 10.1016/j.ctim.2012.12.006. Epub 2013 Jan 8. PMID: 23642947.

34. Wakabayashi H, Oda H, Yamauchi K, Abe F. Lactoferrin for prevention of common viral infections. J Infect Chemother. 2014 Nov; 20 (11): 666-71. DOI: 10.1016/j.jiac.2014.08.003. Epub 2014 Aug 30. PMID: 25182867.

35. Legrand D. Overview of Lactoferrin as a Natural Immune Modulator. J Pediatr. 2016 Jun;173 Suppl: S 10-5. DOI: 10.1016/j.jpeds.2016.02.071. PMID: 27234406.

36. Kruzel ML, Zimecki M, Actor JK. Lactoferrin in a Context of Inflammation-Induced Pathology. Front Immunol. 2017 Nov 6; 8: 1438. DOI: 10.3389/fimmu.2017.01438. PMID: 29163511; PMCID: PMC 5681489.

37. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28; 395 (10229): 1033-1034. DOI: 10.1016/S01406736(20)30628-0. Epub 2020 Mar 16. PMID: 32192578; PMCID: PMC 7270045.

38. Zimecki M, Wtaszczyk A, Zagulski T, Kubler A. Lactoferrin lowers serum interleukin 6 and tumor necrosis factor alpha levels in mice subjected to surgery. Arch Immunol Ther Exp (Warsz). 1998; 46 (2): 97-104. PMID: 9613707.

39. Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. Int J Mol Sci. 2017 Sep 15; 18 (9): 1985. DOI: 10.3390/ijms18091985. PMID: 28914813; PMCID: PMC 5618634.

40. Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents. 2020 Sep; 56 (3): 106118. DOI: 10.1016/j.ijantimicag.2020.106118. Epub 2020 Jul 30. PMID: 32738305; PMCID: PMC 7390755.

41. Box-Amoros A, Collado MC, Van’t Land B, Calvert A, Le Doare K, Garssen J, Hanna H, Khaleva E, Peroni DG, Geddes DT, Kozyrskyj AL, Warner JO, Munblit D. Reviewing the evidence on breast milk composition and immunological outcomes. Nutr Rev. 2019 May 21: nuz 019. DOI: 10.1093/nutrit/nuz019. Epub ahead of print. PMID: 31111150.

42. Morrin S. T., Buck R. H., Farrow M., Hickey R. M., Milk-derived anti-infectives and their potential to combat bacterial and viral infection, Journal of Functional Foods, Volume 81, 2021. p. 104442. https://doi.org/10.1016/j.jff.2021.104442

43. Walker WA, Iyengar RS. Breast milk, microbiota, and intestinal immune homeostasis. Pediatr Res. 2015 Jan; 77 (1-2): 220-8. DOI: 10.1038/pr.2014.160. Epub 2014 Oct 13. PMID: 25310762.

44. Duijts L, Jaddoe VW, Hofman A, Moll HA. Prolonged and exclusive breastfeeding reduces the risk of infectious diseases in infancy. Pediatrics. 2010 Jul; 126 (1): e18-25. DOI: 10.1542/peds.2008-3256. Epub 2010 Jun 21. PMID: 20566605.

45. Rebhan B, KohlhuberM, Schwegler U, Fromme H, Abou-Dakn M, Koletzko BV. Breastfeeding duration and exclusivity associated with infants’ health and growth: data from a prospective cohort study in Bavaria, Germany. Acta Paediatr. 2009 Jun; 98 (6): 974-80. DOI: 10.1111/j.1651-2227.2009.01281.x. PMID: 19484835.

46. Marchetti M, Superti F, Ammendolia MG, Rossi P, Valenti P, Seganti L. Inhibition of poliovirus type 1 infection by iron-, manganese- and zinc-saturated lactoferrin. Med Microbiol Immunol. 1999 May; 187 (4): 199-204. DOI: 10.1007/s004300050093. PMID: 10363676.

47. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May; 92 (5): 479-490. DOI: 10.1002/jmv.25707. Epub 2020 Mar 3. PMID: 32052466; PMCID: PMC 7166986.

48. Konishi M, Iwasa M, Yamauchi K, Sugimoto R, Fujita N, Kobayashi Y, Watanabe S, Teraguchi S, Adachi Y, Kaito M. Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res. 2006 Sep; 36 (1): 27-32. DOI: 10.1016/j.hepres.2006.06.005. Epub 2006 Jul 20. PMID: 16857423.

49. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP, Melendez AJ. Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunol. 2005 Jan 18; 6: 2. DOI: 10.1186/1471-2172-6-2. PMID: 15655079; PMCID: PMC 546205.

50. Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004 Jun; 49 (6): 1036-9. DOI: 10.1023/b:ddas.0000034568.69407.47. PMID: 15309897.

51. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanau-er SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98 (6): 1309-14. DOI: 10.1111/j.1572-0241.2003.07458.x. PMID: 12818275.

52. Ishikado A, Imanaka H, Takeuchi T, Harada E, Makino T. Liposomalization of lactoferrin enhanced it’s anti-inflammatory effects via oral administration. Biol Pharm Bull. 2005 Sep; 28 (9): 1717-21. DOI: 10.1248/bpb.28.1717. PMID: 16141546.

53. Serrano, G., Kochergina, I., Albors, A., D^az, E., Oroval, M., Hueso, G., & Serrano, J. Liposomal Lactoferrin as Potential Preventative and Cure for COVID-19. Int J Res Health Sci 2020; 8: 8-15.

54. Bruni N, Capucchio MT, Biasibetti E, Pessione E, Cirrincione S, Giraudo L, Corona A, Dosio F. Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine. Molecules. 2016 Jun 11; 21 (6): 752. DOI: 10.3390/molecules21060752. PMID: 27294909; PMCID: PMC 6273662.

55. Wang Y, Wang P, Wang H, Luo Y, Wan L, Jiang M, Chu Y. Lactoferrin for the treatment of COVID-19 (Review). Exp Ther Med. 2020 Dec; 20 (6): 272. DOI: 10.3892/etm.2020.9402. Epub 2020 Oct 27. PMID: 33199997; PMCID: PMC 7664603.

56. Peroni DG, Fanos V. Lactoferrin is an important factor when breastfeeding and COVID-19 are considered. Acta Paediatr. 2020 Oct; 109 (10): 2139-2140. DOI: 10.1111/apa.15417. Epub 2020 Jun 28. PMID: 32557901; PMCID: PMC 7323098.

57. Campione E, Lanna C, Cosio T, Rosa L, Conte MP, Iacovelli F, Romeo A, Falconi M, Del Vecchio C, Franchin E, Lia MS, Minieri M, Chiaramonte C, Ciotti M, Nuccetelli M, Terrinoni A, Iannuzzi I, Coppeda L, Magrini A, Bernardini S, Sabatini S, Rosapepe F, Bartoletti PL, Moricca N, Di Lorenzo A, Andreoni M, Sarmati L, Miani A, Piscitelli P, Valenti P, Bianchi L. Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences. Front Pharmacol. 2021 Jun 17; 12: 666600. DOI: 10.3389/fphar.2021.666600. PMID: 34220505; PMCID: PMC 8242182.

58. Campione, E, Lanna, C, Cosio, T, et al. Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients: in vitro and in vivo preliminary evidences [published online ahead of print 2020]. https://www.biorxiv.org/content/10.1101/2020.08.11.244996v4.full.pdf. DOI: https://doi.org/10.1101/2020.08.11.244996

59. ClinicalTrials.gov. Lactoferrin in Covid-19 Hospitalized Patients (LAC) https://clinical-trials.gov/ct2/show/NCT04847791

60. ClinicalTrials.gov. Lactoferrin for Prevention of COVID-19 in Health Care Workers (LF-COVID). https://clinicaltrials.gov/ct2/show/NCT04526821


Для цитирования:


Орлова С.В., Никитина Е.А., Прокопенко Е.В., Волкова Л.Ю., Водолазкая А.Н. Иммунонутриентные свойства лактоферрина и его защитная роль при новой коронавирусной инфекции COVID-19. Медицинский алфавит. 2021;(21):22-26. https://doi.org/10.33667/2078-5631-2021-21-22-26

For citation:


Orlova S.V., Nikitina E.A., Prokopenko E.V., Volkova L.Yu., Vodolazkaya A.N. Immune properties of lactoferrin and its protective role in new coronavirus infection COVID-19. Medical alphabet. 2021;(21):22-26. (In Russ.) https://doi.org/10.33667/2078-5631-2021-21-22-26

Просмотров: 107


ISSN 2078-5631 (Print)